Unlock instant, AI-driven research and patent intelligence for your innovation.

Methods of generating populations of tumour-infiltrating T cells

A tumor-infiltrating, tumor-cell technique for the generation of T-cell populations of scientific, diagnostic or therapeutic relevance

Pending Publication Date: 2018-11-16
LYTIX BIOPHARMA
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It is believed that this will lead to the release of TAA for a more complete library

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods of generating populations of tumour-infiltrating T cells
  • Methods of generating populations of tumour-infiltrating T cells
  • Methods of generating populations of tumour-infiltrating T cells

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0214] LTX-315 disintegrates the plasma membrane of osteosarcoma cells

[0215] 1 Materials and methods

[0216] Plasma membrane disintegration was performed as described in FORVEILLE S. et al., Cell Cycle 2015, 14:3506-12.

[0217] 1.1 Chemicals and cell culture

[0218] Media and supplements for cell culture were obtained from Gibco-Life Technologies (Carlsbad, CA, USA), except from Lytix Biopharma ( Norway) provided chemicals other than LTX-315 (K-K-W-W-K-K-W-Dip-K-NH2) from Sigma-Aldrich (St. Louis, MO, USA); plastics were from Greiner Bio-One (Monroe, CA, USA).

[0219] Human osteosarcoma U2OS cells were cultured in Glutamax-containing DMEM medium supplemented with 10% fetal calf serum (FCS) and 10MM HEPES buffer. At 37 °C in a humidified incubator at 5% CO 2 Cells were grown under atmosphere.

[0220] 1.2 Transmission electron microscopy

[0221] For ultramicrostudies, human osteosarcoma U2OS cells were fixed in 1.6% glutaraldehyde (v / v, dissolved in 0.1M ...

Embodiment 2

[0225] LTX-315 internalizes and interacts with mitochondria

[0226] In this study, we investigated the tumoricidal effect of LTX-315 on human melanoma cells. The peptide is internalized and shown to associate with mitochondria, ultimately leading to lytic cell death. Intratumoral injection of LTX-315 peptide to treat solid tumors through the following two-stage mode of action: the first stage is the collapse of the tumor itself, and the second node is the release of damage-associated molecular pattern molecules (DAMPs) by dying tumor cells , which is capable of inducing subsequent immune protection against relapse and metastasis.

[0227] 1 Materials and methods

[0228] Studies were performed as described in FORVEILLE S. et al., Cell Cycle 2015, 6:34910-23.

[0229] 1.1 Reagents

[0230] LTX-315 and LTX-328 (K-A-Q-Dip-Q-K-Q-A-W-NH 2 ). Respectively from Innovagen (Lund, Sweden) and ( Norway) purchased LTX-315Pacific Blue and LTX-328Pacific Blue.

[0231] 1.2...

Embodiment 3

[0271] LTX-401 induces DAMP release from melanoma cells

[0272] In this study, we examined the ability of the amino acid derivative LTX-401 to induce cell death in cancer cell lines, and to induce regression in a murine melanoma model. In vitro mode of action studies revealed lytic cell death and release of hazard-associated molecular pattern molecules, preceded by massive cytoplasmic vacuolization and destruction of lysosomes in treated cells. Using a murine melanoma model, most animals treated with intratumoral injections of LTX-401 exhibited complete and durable remissions. Taken together, these results suggest the potential of LTX-401 as an immunotherapeutic agent for the treatment of solid tumors.

[0273] 1 Materials and methods

[0274] 1.1 Reagents

[0275] LTX-401 (Mw net = 367.53). The chemical structure is shown in Figure 11 middle.

[0276] 1.2 Cell culture

[0277] JM1, rat hepatocellular carcinoma, HEPG2 and BEL7402, both human hepatocellular ca...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a method of generating a population of tumour-infiltrating T cells, said method comprising administering to a subject a positively charged amphipathic amino acid derivative, peptide or peptidomimetic which is able to lyse tumour cell membranes and then collecting a cellular sample from a tumour within said subject and separating T cells therefrom. The present invention further provides a method of generating a population of tumour-infiltrating T cells, said method comprising separating T cells from a cellular tumour sample taken from a subject treated with a positively charged amphipathic amino acid derivative, peptide or peptidomimetic which is able to lyse tumour cell membranes and optionally culturing said T cells. The present invention also provides the tumour-infiltrating T cells described above for use in treating tumour cells or preventing or reducing the growth, establishment, spread, or metastasis of a tumour.

Description

technical field [0001] The present invention relates to the field of cancer therapy and related research. In particular, the present invention provides methods for generating scientifically, diagnostically or therapeutically relevant T cell populations. Background technique [0002] The incidence of cancer in human and animal populations and its role in mortality means that there is a continuing need for new therapies against tumors and tumor cells. Eliminating a tumor, reducing its size, interrupting its supporting vasculature, or reducing the number of cancer cells circulating in the blood or lymphatic system may be beneficial in various ways; for example by reducing pain or discomfort, preventing metastasis, facilitating surgical intervention, or prolonging life. [0003] Cancer therapies designed against tumors or cells metastasized from tumors often rely on cytotoxic activity. This activity may be a cytotoxic effect of the agent itself, or it may be an effect of indi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K35/17C07K7/06C12N5/0783A61K38/04
CPCC12N5/0638A61K38/04C07K7/06A61P35/00A61K2239/57A61K39/46449A61K39/4611C07K14/4748A61K38/00A61K35/17C07K4/00C07K14/00
Inventor 凯蒂尔·安多·凯米莉欧詹妮·梅里思·内斯特沃尔德巴尔德尔·斯文布约恩森埃斯泰因·瑞克多
Owner LYTIX BIOPHARMA